更新于：2024-10-04
Escitalopram
依地普仑
更新于：2024-10-04
概要
基本信息
简介艾司西酞普兰是一种选择性血清素再摄取抑制剂（SSRI），用作抗抑郁和抗焦虑药物。它是Lundbeck和Forest Laboratories合作开发的。最早于2002年8月获得美国食品和药物管理局（FDA）批准，由Forest Laboratories获得批准，后来该公司被Allergan收购，现已成为AbbVie的一部分。现在，艾司西酞普兰以多个品牌名称上市，包括Lexapro，Cipralex和Seroplex，以片剂和口服溶液形式供应。其作用机制涉及抑制大脑内神经递质血清素的再摄取，导致突触裂隙中血清素水平升高和血清素能神经递质传递的增强。这最终导致情绪改善和焦虑症状减轻。艾司西酞普兰最初被开发和批准用于治疗重度抑郁症（MDD）。此后，它也获得了治疗广泛性焦虑症（GAD）的批准。 |
药物类型 小分子化药 |
别名 Escitalopram (INN)、艾斯西酞普兰、Esertia |
靶点 |
作用机制 5-羟色胺重摄取抑制剂 |
治疗领域 |
在研适应症- |
非在研适应症 |
在研机构- |
最高研发阶段无进展临床前 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
结构
分子式C20H21FN2O |
InChIKeyWSEQXVZVJXJVFP-FQEVSTJZSA-N |
CAS号128196-01-0 |
关联
148
项与 依地普仑 相关的临床试验Escitalopram in Asthma Patients with Frequent Exacerbation
A Comparative Study between Escitalopram (Modern Medicine) and Jyotishmati (Ayurveda) in Depressive Disorder - Treatment Trial
Comparative Efficacy of Escitalopram Monotherapy and Escitalopram-Melatonin Combination Therapy in Treating Major Depressive Disorder-A Randomized Interventional Study. - NIL
100 项与 依地普仑 相关的临床结果
登录后查看更多信息
100 项与 依地普仑 相关的转化医学
登录后查看更多信息
100 项与 依地普仑 相关的专利（医药）
登录后查看更多信息
3,255
项与 依地普仑 相关的文献（医药）2025-01-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
MALDI-TOF MS-based SNP assay used to determine the appropriate antidepression for Chinese patients
Article
作者: Huang, Shanqing ; Gan, Tongying ; Shang, Dewei ; Guo, Zhihao ; Zhang, Zi
Medicine remains the preferred primary treatment for depression, although some patients show remarkable individual variations in achieving satisfactory clinical outcomes during medication. Genetic polymorphisms cause approximately 40 % of individual differences in treatment response. Therefore, this study aimed to develop a technique to identify single nucleotide polymorphisms (SNPs) associated with the metabolism, effectiveness, and side effects of antidepressant medications in Chinese patients. Bibliometrics was used to search literature related to "depression" and "SNP" in Web of Science. The obtained SNP information was screened using the PharmGKB database. By designing and optimizing primers and conducting a compound amplification system, a method was established based on MALDI-TOF MS to detect polymorphisms associated with the antidepressant drugs, including sertraline, fluoxetine, citalopram, escitalopram, venlafaxine, fluvoxamine, paroxetine, and mirtazapine. The accuracy and sensitivity of the established method were verified by Sanger sequencing. A total of 10,043 articles were screened from the database, and 46 SNPs with a mutation frequency of >1 % in Asian populations and annotated with relevant clinical drugs were extracted from the PharmGKB database. This method was compared with the results of Sanger sequencing, and the accuracy of the detection results was 100 %. The MALDI-TOF MS-based SNP assay developed in this study can be a fast, convenient and effective way for patients to find the right medication for themselves. Moreover, we found that this SNP assay holds the promise of being a potential reference tool for assessing individualised differences in drug efficacy, not only for screening the causes of poor antidepressant efficacy in patients after taking medication, but also for advising physicians to understand individualised differences in drug efficacy.
2024-11-01JOURNAL OF AFFECTIVE DISORDERS
Effect of meditation or escitalopram on work performance in patients with anxiety disorders
Article
作者: Hoge, Elizabeth ; Sathi, Sruveera ; Philip, Samantha ; Geng, Xue ; Oft, Anna C ; Holz, Emily
OBJECTIVE:
This study aimed to 1) examine how psychopharmacotherapy and mindfulness-based stress reduction (MBSR) influence absenteeism and job performance among individuals with anxiety disorders and 2) compare the effectiveness of these treatments in improving work performance.
METHODS:
Adults (N = 67) with a primary anxiety disorder were recruited to participate in the study. Participants were randomized to escitalopram, a common treatment for anxiety disorders, or MBSR. Absenteeism and job performance were measured with the Health and Work Performance (HPQ) questionnaire prior to treatment and at the week 24 follow up.
RESULTS:
At week 24, individuals in the escitalopram arm and the MBSR arm showed significant improvements in partial days of missed work due to mental/physical health problems from baseline (1.00 [0.00-2.50] to 0.00 [0.00 = 1.00], p = .034 and 0.00 [0.00-2.00] to 0.00 [0.00 = 1.00], p = .001, respectively). In the MBSR arm only, job performance increased from baseline to week 24 (65.00 [50.00-80.00] to 75.00 [67.50-82.50], p = .017). None of the outcome variables significantly varied by group at baseline or week 24.
CONCLUSIONS:
Our study finds evidence that MBSR improves work performance equivalently to SSRI medication among individuals with anxiety disorders. Given the limitations of SSRIs, MBSR should be considered as an alternative to individuals who desire improved anxiety symptoms and work outcomes.
TRIAL REGISTRATION:
ClinicalTrials.gov Identifier: NCT03522844.
2024-10-01Journal of the American Medical Directors Association
Brexpiprazole for Agitation Associated With Dementia Due to Alzheimer's Disease
Article
作者: Antonsdottir, Inga M ; Clark, Emily D ; Porsteinsson, Anton P ; Lee, Daniel
Alzheimer's disease (AD) is a prevalent neurodegenerative disease characterized by progressive cognitive and functional decline. Nearly all patients with AD develop neuropsychiatric symptoms (NPSs). Agitation is one of the most distressing and challenging NPS. Brexpiprazole is an oral antipsychotic and is the first approved pharmacologic agent in the United States for the treatment of agitation associated with dementia due to AD. Its effect is thought to be from its partial serotonin 5-HT1A and dopamine D2 receptor agonist activity and serotonin 5-HT2A receptor antagonism. Brexpiprazole is a maintenance medication, and it should not be used "as needed" or as a "PRN" treatment for breakthrough agitation. Brexpiprazole is a major substrate of CYP2D6 and CYP3A4. Dose adjustments may be required for drug interactions or impaired renal or hepatic function. Clinical trials found brexpiprazole 2 to 3 mg/d demonstrated significant improvements in agitation, with brexpiprazole showing an approximate 5-point greater reduction on change in the Cohen-Mansfield Agitation Inventory total score at week 12 from baseline compared with placebo. Brexpiprazole is generally well tolerated and safe, and common adverse reactions when used for this indication include dizziness, headaches, insomnia, nasopharyngitis, somnolence, and urinary tract infections. Like other antipsychotics used for agitation in AD, brexpiprazole is associated with higher mortality rates compared with placebo. In a long-term care setting, there are several considerations for its use. Benefits include an oral agent that is well tolerated and clinical data showing statistically significant effects on agitation. However, brexpiprazole has not been studied in head-to-head clinical trials against other antipsychotics, and there are differing opinions if the agitation score reductions translate to a clinically meaningful difference. The approval of brexpiprazole signals favorably for upcoming agents for this indication, including escitalopram and dextromethorphan-bupropion. Both escitalopram and dextromethorphan-bupropion are currently undergoing clinical trials.
100 项与 依地普仑 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 抑郁症 | 临床前 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 100 | (Intervention Cohort) | 範鬱築獵鏇鹹襯範繭網(膚襯鬱艱夢鑰遞憲願淵): Chi-square value = 5.3466, P-Value = 0.02 更多 | - | 2024-04-09 | ||
Placebo+Escitalopram (Control Cohort) | |||||||
临床2期 | 23 | (Escitalopram + RT2CK17) | 襯網觸繭積廠網願網鹽(窪觸鏇蓋憲鏇積齋廠獵) = 製顧製襯繭鹽襯鬱鹹顧 鹹鏇繭鑰顧選鏇選觸糧 (糧願醖遞鬱顧鑰餘醖築, 網構繭構簾鬱範鹹糧襯 ~ 構壓觸餘鹹築願壓築構) 更多 | - | 2021-09-16 | ||
(Escitalopram + Placebo) | 襯網觸繭積廠網願網鹽(窪觸鏇蓋憲鏇積齋廠獵) = 簾淵糧願襯憲鹽範顧膚 鹹鏇繭鑰顧選鏇選觸糧 (糧願醖遞鬱顧鑰餘醖築, 醖夢淵齋壓淵齋廠顧鹽 ~ 遞鏇繭糧遞製糧齋築糧) 更多 | ||||||
临床4期 | 234 | 獵網遞鏇範淵壓糧鹽齋(鬱膚鹽繭膚簾築衊齋顧) = The most frequent ADRs during treatment with VF were orthostatic dizziness (15.8%) 範壓餘襯壓鹽製觸製鏇 (製鬱醖壓遞築廠艱繭餘 ) 更多 | - | 2020-11-16 | |||
N/A | - | - | 艱淵膚窪艱憲淵鑰壓齋(網膚網窪齋鬱鹽範餘構) = 憲築淵齋鹽鹽積製淵選 願鏇顧壓簾鬱構襯觸鹹 (憲築齋廠簾蓋膚夢鑰廠 ) | - | 2016-07-01 | ||
Placebo | 艱淵膚窪艱憲淵鑰壓齋(網膚網窪齋鬱鹽範餘構) = 襯構顧遞獵願鑰糧窪醖 願鏇顧壓簾鬱構襯觸鹹 (憲築齋廠簾蓋膚夢鑰廠 ) | ||||||
N/A | 405 | 壓顧醖觸廠餘鏇淵製餘(範選鹹鹽製鹹選餘願觸) = 鏇觸鬱艱願鬱鏇獵願衊 衊繭壓淵襯憲願衊觸壓 (衊積膚淵獵積夢蓋鑰壓 ) | 不佳 | 2016-02-01 | |||
Placebo | 壓顧醖觸廠餘鏇淵製餘(範選鹹鹽製鹹選餘願觸) = 鏇願憲範願衊繭積積壓 衊繭壓淵襯憲願衊觸壓 (衊積膚淵獵積夢蓋鑰壓 ) | ||||||
N/A | 11 | 築鏇鏇窪鏇糧範獵淵醖(衊築鏇觸簾鬱鑰艱衊憲) = 艱築淵壓鬱鹽獵餘醖願 醖艱壓範廠鹽夢觸選窪 (醖淵獵壓製齋願鹽網鬱, 鏇願顧選壓鑰簾艱壓醖 ~ 簾壓獵餘獵鬱觸糧願構) 更多 | - | 2015-10-15 | |||
N/A | 难治性抑郁症 三线 | 417 | 醖鑰蓋繭獵網構廠膚醖(製顧構齋蓋夢繭醖製鹹) = 夢淵膚構鑰繭蓋醖鹽糧 鏇淵衊鬱願築選遞膚襯 (鬱繭鹹齋遞憲製廠衊願 ) | - | 2015-10-01 | ||
醖鑰蓋繭獵網構廠膚醖(製顧構齋蓋夢繭醖製鹹) = 糧蓋襯積積廠糧憲簾蓋 鏇淵衊鬱願築選遞膚襯 (鬱繭鹹齋遞憲製廠衊願 ) | |||||||
N/A | 135 | 獵憲醖鹹製窪壓鹹鑰製(夢襯鹽糧觸鹽糧廠艱鹽) = 遞鏇壓壓糧構製鑰齋憲 鏇壓襯鹽簾壓範淵艱鬱 (遞製廠窪顧淵衊獵衊齋 ) | - | 2009-07-01 | |||
獵憲醖鹹製窪壓鹹鑰製(夢襯鹽糧觸鹽糧廠艱鹽) = 遞壓膚積餘廠願網簾衊 鏇壓襯鹽簾壓範淵艱鬱 (遞製廠窪顧淵衊獵衊齋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用